Costs and effects of telerehabilitation in neurological and cardiological diseases: A systematic review
dc.contributor.author | Del Pino Sáez, Rocío | |
dc.contributor.author | Díez Cirarda, María | |
dc.contributor.author | Ustarroz Aguirre, Iker | |
dc.contributor.author | González Larragán, Susana | |
dc.contributor.author | Caprino, Massimo | |
dc.contributor.author | Busnatu, Stefan | |
dc.contributor.author | Gand, Kai | |
dc.contributor.author | Schlieter, Hannes | |
dc.contributor.author | Gabilondo Cuellar, Iñigo | |
dc.contributor.author | Gómez Esteban, Juan Carlos | |
dc.date.accessioned | 2023-01-30T18:33:33Z | |
dc.date.available | 2023-01-30T18:33:33Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Frontiers in Medicine 9 : (2022) // Article ID 832229 | es_ES |
dc.identifier.issn | 2296-858X | |
dc.identifier.uri | http://hdl.handle.net/10810/59566 | |
dc.description.abstract | Introduction: Telerehabilitation in neurological and cardiological diseases is an alternative rehabilitation that improves the quality of life and health conditions of patients and enhances the accessibility to health care. However, despite the reported benefits of telerehabilitation, it is necessary to study its impact on the healthcare system. Methods: The systematic review aims to investigate the costs and results of telerehabilitation in neurological and cardiological diseases. MEDLINE and EMBASE databases were searched from 2005 to 2021, for studies that assess the costs and results of telerehabilitation compared to traditional rehabilitation (center-based programs) in neurological and cardiological diseases. A narrative synthesis of results was carried out. Results: A total of 8 studies (865 participants) of 430 records were included. Three studies were related to the costs and results of telerehabilitation in neurological diseases (specifically in stroke). In total, five studies assessed telerehabilitation in cardiological diseases (chronic heart failure, coronary heart disease, acute coronary syndrome, and cardiovascular diseases). The duration of the telerehabilitation ranged from 6 to 48 weeks. The studies included cost-analysis, cost-benefit, cost-effectiveness, or cost-utility. In total, four studies found significant cost/savings per person between $565.66 and $2,352.00 (p < 0.05). In contrast, most studies found differences in costs and clinical effects between the telerehabilitation performed and the rehabilitation performed at the clinic. Just one study found quality-adjusted life years (QALY) significant differences between groups [Incremental cost-effectiveness ratio (ICER) per QALY ($-21,666.41/QALY). Discussion: Telerehabilitation is an excellent alternative to traditional center rehabilitation, which increases the accessibility to rehabilitation to more people, either due to the geographical situation of the patients or the limitations of the health systems. Telerehabilitation seems to be as clinical and cost-effective as traditional rehabilitation, even if, generally, telerehabilitation is less costly. More research is needed to evaluate health-related quality of life and cost-effectiveness in other neurological diseases. | es_ES |
dc.description.sponsorship | This project has received funding from the European Union's Horizon 2020 Research and Innovation Program under grant agreement no: 769807. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/769807 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.subject | cost-effectiveness | es_ES |
dc.subject | telerehabilitation | es_ES |
dc.subject | cardiological diseases | es_ES |
dc.subject | neurological disease | es_ES |
dc.subject | systematic review | es_ES |
dc.title | Costs and effects of telerehabilitation in neurological and cardiological diseases: A systematic review | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.holder | © 2022 Del Pino, Díez-Cirarda, Ustarroz-Aguirre, Gonzalez-Larragan, Caprino, Busnatu, Gand, Schlieter, Gabilondo and Gómez-Esteban. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | es_ES |
dc.rights.holder | Atribución 3.0 España | * |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fmed.2022.832229/full | es_ES |
dc.identifier.doi | 10.3389/fmed.2022.832229 | |
dc.contributor.funder | European Commission | |
dc.departamentoes | Neurociencias | es_ES |
dc.departamentoeu | Neurozientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2022 Del Pino, Díez-Cirarda,
Ustarroz-Aguirre, Gonzalez-Larragan,
Caprino, Busnatu, Gand, Schlieter,
Gabilondo and Gómez-Esteban. This is
an open-access article distributed
under the terms of the Creative
Commons Attribution License (CC BY).
The use, distribution or reproduction in
other forums is permitted, provided
the original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution
or reproduction is permitted which
does not comply with these terms.